<sup>18</sup>F-氟脱氧葡萄糖PET在原发陛肝细胞癌中的应用

郑磊; 李前伟; 郑磊; 李前伟

[1]

Lee JD, Yang WI, Park YN, et al. Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased ¹⁸F-FDG uptake[J]. J Nucl Med, 2005, 46(10):1753-1759.

[2]

Yu Kuang, Schomisch SJ, Chandramouli V, et al. Hexokinase and glu-cose-6-phosphatase activity in woodchuck model of hepatitis virus-induced hepatocellular carcinoma[J]. Comp Biochem Physiol, C Toxicol Pharmacol, 2006, 143(2):225-231.

[3]

Torizuka T, Tamaki N, Inokuma T, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET[J]. J Nucl Med, 1995, 36(10):1811-1817.

[4]

李正平,周杰,张峻,等.¹⁸F-FDG PET在原发性肝癌中的诊断作用[J].肝胆外科杂志,2005,13(5):351-354.

[5]

Seo S, Hatano E, Higashi T, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, Pglycoprotein expression, and outcome after resection in hepatocellular carcinoma[J]. Clin Cancer Res, 2007, 13(2Pt 1):427-433.

[6]

Yang SH, Suh KS, Lee HW, et al. The role of ¹⁸F-FDG-PET imaging for the selection of liver transplavtation candidates from among hepatocellular carcinoma patients[J]. Transplantation, 2006, 82(1 Suppl 2):350.

[7]

Iwata Y, Shiomi S, Sasaki N, et al. Clinical usefulness of positron emissiontomography with fluorine-18-fluorodeoxyglucose in the diagnosis of livertumors[J]. Ann Nucl Med, 2000, 14(2):121-126.

[8]

Jeng LB, Changlai SP, Shen YY, et al. Limited value of ¹⁸F-2-deoxyglucose positron emission tomography to detect hepatocellular carcinoma in hepatitis B virus carriers[J]. Hepatogastroenterology, 2003, 50(54):2154-2156.

[9]

Kurtaran A, Becherer A, Pfeffel F, et al. ¹⁸F-fluorodeoxyglucose (FDG)-PET features of focal nodular hyperplasia(FNH) of the liver[J]. Liver, 2000, 20(6):487-490.

[10]

Sugiyama M, Sakahara H, Torizuka T, et al. ¹⁸F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma[J]. J Gastroenterol, 2004, 39(10):961-968.

[11]

Kuker RA, Mesoloras G, Gulec SA. Optimization of FDG-PET/CT imaging protocol for evaluation of patients with primary and metastatic liver disease[J]. Int Semin Surg Oncol, 2007, 4:17.

[12]

Wudel LJ, Delbeke D, Morris D, et al. The role of[¹⁸F] fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma[J]. Am Surg, 2003, 69(2):117-124.

[13]

Lai P, Bomanji JB, Mahmood S, et al. Detection of tumour thrombus by ¹⁸F-FDG-PET/CT imaging[J]. Eur J Cancer Prey, 2007, 16(1):90-94.

[14]

Ludwig V, Hopper OW, Martin WH, et al. ¹⁸F-Fluorodeoxyglucose positron emission tomography surveillance of hepatic metastases from prostate cancer following radiofrequency ablation; a case report[J]. Am Surg, 2003, 69(7):593-598.

[15]

赵明,吴沛宏,曾益新,等.¹⁸FDG-PET/CT对评价TACE联合RFA治疗原发性肝癌的效果的价值[J].癌症,2005,24(9):1118-1123.

[16]

谭志斌,赵明,吴沛宏,等.¹⁸F-FDG PET/CT在原发性肝癌介入治疗中的价值[J].介入放射学杂志,2005,14(6):588-591.

[17]

Blokhuis TJ,Van Der Schoof MC,Van Den Tol MP, et al. Results of radio frequency ablation of primary and secondary liver tumors:Long-term follow-up with computed tomography and positron emission tomography-¹⁸F-deoxyfluoroglucose scanning. Scand J Gastroenterol Suppl, 2004, (241):93-97.

[18]

商健彪,李彦豪,刘方颖,等.¹⁸F-FDG PET显像在肝细胞癌介入治疗后残留病灶检出中的应用[J].中华核医学杂志,2004,24(6):325-327.

[19]

Szyszko T, AF Nahhas A, Canelo R, et al. Assessment of response to treatment of unresectable liver tumours with ⁹⁰Y microspheres:Value of FDG PET versus computed tomography[J]. Nucl Med Commun, 2007, 28(1):15-20.

[20]

Wang XL, Li H, Wang QS, et al. Clinical value of pre-and postoperative ¹⁸F-FDG PET/CT in patients undergoing liver transplantatiOn for hepatocellular carcinoma[J]. J South Med Univ, 2006, 26(8):1087-1091.

[21]

蒋宁一,张弘,王捷,等.25例肝癌术后患者¹⁸F-FDG SPECT/CT同机融合显像分析[J].生物医学工程与临床,2004,8(2):100-102.

[22]

Kong YH, Han CJ, Lee SD, et al. Positron emission tomography with fluorine-18-fluorodeoxyglucose is useful for predicting the prognosis of patients with hepatocellular carcinoma[J]. Korean J Hepatol, 2004, 10(4):279-287.